$206 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 32 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -40,000 | -100.0% | -0.11% | – |
ADVM | Exit | ADVERUM BIOTECHNOLOGIES INCcall | $0 | – | -100,000 | -100.0% | -0.28% | – |
CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -35,000 | -100.0% | -0.34% | – |
ACST | Exit | ACASTI PHARMA INCcl a new | $0 | – | -620,000 | -100.0% | -0.38% | – |
MDCO | Exit | MEDICINES CO | $0 | – | -21,700 | -100.0% | -0.46% | – |
KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -107,500 | -100.0% | -0.47% | – |
IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -150,000 | -100.0% | -0.79% | – |
ZYME | Exit | ZYMEWORKS INC | $0 | – | -70,500 | -100.0% | -0.79% | – |
ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -100,000 | -100.0% | -0.85% | – |
INSM | Exit | INSMED INC | $0 | – | -169,000 | -100.0% | -1.00% | – |
NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -372,500 | -100.0% | -1.14% | – |
MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -508,500 | -100.0% | -2.02% | – |
KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -590,000 | -100.0% | -2.80% | – |
ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -587,089 | -100.0% | -4.99% | – |
XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -500,000 | -100.0% | -11.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.